Patients with low pulmonary vascular resistance may benefit from complex procedure for PH

May 18, 2014

Patients with chronic pulmonary thromboembolic disease may benefit from pulmonary thromboendarterectomy (PTE), even if the patients don't have severe pulmonary hypertension, according to University of California, San Diego, researchers.

The study was presented at the 2014 American Thoracic Society International Conference.

UCSD pioneered PTE in the 1970s for who suffered from chronic thromboembolic pulmonary hypertension (CTEPH). During PTE, surgeons put a patient on a heart-lung machine, cool the body to reduce its need for oxygen and then turn the machine off for up to 20 minutes so they can remove clots and scar tissue from the patient's arteries. Because of the procedure's complexity, it has been used, until recently, only to help patients whose pulmonary thromboembolic disease causes severe hypertension and has not responded to other therapies.

"Over the past five years, an increasing number of patients with symptomatic chronic thromboembolic disease, without severe pulmonary hypertension, are being offered and choosing to undergo the surgery, said lead investigator Daniel Crouch, MD, a third-year pulmonary and critical care fellow at UCSD. "These patients have symptoms that create a major burden in their lives. However, given that they do not have severe pulmonary hypertension and cardiac dysfunction, the benefits of the surgery must greatly outweigh the risks. "

In a retrospective chart review of patients who underwent PTE at UCSD between July 2010 and June 2013, Crouch found that 64 subjects had pre-operative pulmonary resistance values (PVRs) less than 300 dyn∙/cm5 and 355 patients had PVRs above 300dyn∙/cm5. (The value is used at UCSD as a guide to identify patients with severe and non-severe .) In the UCSD study, both groups had similar mean age and gender composition, while the (32.57 vs 30.18) was higher in the low PVR group.

Crouch and his colleagues found that those in the low PVR group had lower mortality (0 vs. 1.1%) and fewer complications, including delirium (7.8% vs. 14.9%), pneumonia/tracheobronchitis (6.3% vs. 15.5%), and a statistically significant lower rate of reperfusion lung injury (7.8% vs. 25.9%), The low PVR group also experienced statistically significant recoveries, with less time spent on the ventilator (1.7 vs. 3.2 days), in the ICU (4 vs. 5.8 days) and in the hospital (13 vs. 16.3 days).

Anecdotally, Crouch added, patients in the low PVR group showed "great benefit" in follow up visits. Nonetheless, the program is conducting a follow-up study to evaluate formally improvement in their functional status and quality of life. With higher (BMI) and a higher rate of simultaneous coronary artery bypass grafting (9.4% vs. 15.5%), he said, those in the low group may have other factors that contribute to their symptoms before surgery.

"Although pulmonary thromboendarterectomy is the procedure of choice for CTEPH, there are important questions to answer before it can be considered the treatment of choice in the low PVR patient population," Crouch said. "As with anything we offer patients, we want to prove it's the best therapy."

Explore further: First guidelines for patients with pulmonary hypertension in sickle cell disease

More information: Pulmonary Thromboendarterectomy In Patients With Chronic Pulmonary Thromboembolic Disease And Low Preoperative Pulmonary Vascular Resistance, Scientific Abstract , 18.08 - Pulmonary Embolism: Acute and Chronic (PC) , D.R. Crouch, P.F. Fedullo, W.R. Auger; UC San Diego - San Diego, CA/US

Related Stories

First guidelines for patients with pulmonary hypertension in sickle cell disease

March 18, 2014
Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) physicians have helped create the first set of clinical guidelines for treating patients with pulmonary hypertension in sickle cell disease. Elizabeth ...

Pulmonary hypertension deaths have increased over past decade, according to CDC report

April 3, 2014
Deaths from pulmonary hypertension have increased over the past decade, according to a study from the Centers for Disease Control and Prevention (CDC).

Adempas approved to treat pulmonary hypertension

October 9, 2013
(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

ATS releases guidelines on the management of pulmonary hypertension of sickle cell disease

March 15, 2014
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.

Protein molecule may improve survival in deadly lung disease

May 6, 2014
Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to ...

Macitentan cuts morbidity, death in pulmonary arterial HTN

August 29, 2013
(HealthDay)—For patients with pulmonary arterial hypertension, the new dual endothelin-receptor antagonist macitentan is associated with reductions in morbidity and mortality, according to a study published in the Aug. ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.